|
|
|
| The Nuclear Renaissance: The Expanding Promise Of Radiopharmaceuticals | This Drug Discovery Live panel explores the scientific, clinical, and commercial forces shaping the next generation of radiopharmaceuticals. Experts will discuss emerging alpha- and beta-emitting therapies, targeting advances, manufacturing challenges, and clinical lessons. Gain insights into underserved opportunities and how to position your pipeline in the rapidly evolving nuclear medicine landscape. Register today for the live session on November 19, 2026, at 11 AM ET! |
|
|
|
|
By Ray Dogum, Chief Editor, Drug Discovery Online | Key takeaways from D&D US 2026 on Pfizer’s complex oncology targets, AI-enabled discovery, and the shift toward human-based NAMs. | |
|
|
|
Drugging The tRNA Control System | By Mahmoud Khatib Al-Ruweidi | Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. |
|
|
|
|
|
|
|
|
| Navigating The Development Of Dry Powder For Inhalation | White Paper | By Beatriz Noriega-Fernandes, Mariam Ibrahim, Rui Cruz, et al., Lonza | A CDMO-authored framework for navigating dry powder inhaler development, covering target product profile definition, API characterization, particle engineering technology selection, and more. |
|
|
|
|
|
|
